Edgar Filing: Coley Pharmaceutical Group, Inc.

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â PFIZER INC

2. Date of Event Requiring Statement (Month/Day/Year)
12/28/2007

3. Issuer Name and Ticker or Trading Symbol
Coley Pharmaceutical Group, Inc. [COLY]

(Last)

(First)

(Middle)

235 EAST 42ND STREET

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

NEW YORK,Â NYÂ 10017

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock	24,423,732 ⁽¹⁾	I	See Footnote 2 ⁽²⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
PFIZER INC 235 EAST 42ND STREET NEW YORK,Â NYÂ 10017	Â	Â X	Â	Â

Signatures

Susan Grant, Assistant Secretary of Pfizer Inc.		01/04/2008
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Includes 23,798,732 shares that were purchased in a tender offer by Corvette Acquisition Corp., including 40,048 shares that are subject to guaranteed delivery procedures.
(2)	Corvette Acquisition Corp. recently completed a tender offer for all of the outstanding shares of the issuer. Corvette Acquisition Corp. is a wholly-owned subsidiary of Pfizer Vaccines LLC. Pfizer Vaccines LLC is a wholly-owned subsidiary of Pfizer Inc.
Â Remarks: ThisÂ reportÂ isÂ beingÂ filedÂ byÂ PfizerÂ Inc.Â onÂ behalfÂ ofÂ itself,Â itsÂ wholly-ownedÂ subsidiaryÂ PfizerÂ VaccinesÂ LLCÂ andÂ itsÂ indirectÂ wholly-owned subsidiaryÂ CorvetteÂ AcquisitionÂ Corp.Â Â CorvetteÂ AcquisitionÂ Corp.Â isÂ aÂ wholly-ownedÂ subsidiaryÂ ofÂ PfizerÂ VaccinesÂ LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.